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Abstract (word count, 192) 
Purpose of review 
Anaerobic bacteria are normal commensals but are also considered 
opportunistic pathogens and have been identified as persistent members of 
the lower airway community in people with cystic fibrosis (CF) of all ages and 
stages of disease. Currently, the role of anaerobic bacteria in CF lower airway 
disease is not well understood. Therefore, this review describes the recent 
studies relating to the potential pathophysiological role(s) of anaerobes within 
the CF lungs. 
Recent findings 
The most frequently identified anaerobic bacteria in the lower airways are 
common to both CF and healthy lungs. Studies have shown that in CF the 
relative abundance of anaerobes fluctuates in the lower airways with reduced 
lung function and increased inflammation associated with a decreased 
anaerobic load. However, anaerobes found within the lower airways also 
produce virulence factors, may cause a host inflammatory response and 
interact synergistically with recognised pathogens. 
Summary 
Anaerobic bacteria are potentially members of the airway microbiota in health 
but could also contribute to the pathogenesis of lower airway disease in CF 
via both direct and indirect mechanisms. A personalised treatment strategy 
that maintains a normal microbial community may be possible in the future. 
Key words: anaerobes, microbial community, respiratory infection.  
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Introduction 
Cystic fibrosis (CF) is the most common lethal inherited condition affecting the 
Caucasian population. Clinical characteristics are caused by the absence or 
reduction of cystic fibrosis transmembrane conductance regulator (CFTR) 
protein function, which perturbs ion channels at the apical membrane of 
epithelial cells and results in a multisystem disease. Disease of the lower 
airways is considered the most important manifestation as it is the cause of 
morbidity and mortality in a large percentage of people [1]. 
Lower airway disease is secondary to chronic bacterial infection and a 
dysregulated host inflammatory response that is dominated by neutrophils [2]. 
Currently, a limited range of bacteria which cause lower airway infection, 
including Staphylococcus aureus, Haemophilus influenzae, Pseudomonas 
aeruginosa and Burkholderia cepacia complex, have been correlated with 
worse outcomes of people with CF (Figure 1) [3]; therefore, they are 
recognised as CF pathogens and are usually targeted by antibiotic treatment 
regimens [4]. These pathogens are routinely detected using aerobic culture-
based methods [5]; however, such methods fail to culture obligate anaerobic 
bacteria whilst non-target facultative anaerobic microorganisms isolated are 
often considered “oropharyngeal flora”.  
During the past decade, unexpected bacterial community richness (number of 
species) within the CF lower airways has been demonstrated [6-12]. 
Furthermore, anoxic niches are known to exist within CF sputum, which 
supports the survival of anaerobic bacteria in the lower airways [13,14]. Many 
anaerobic species detected in CF respiratory samples are also present in the 
microbiota of the oral cavity and in a recent study, periodontal-associated 
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anaerobic bacteria were found in plaque and sputum samples of some people 
with CF [15*]. Therefore, detection of oral-associated bacteria in the lungs 
may be attributed to migration from the oral cavity to the lower airways [16-
18].  
Despite the accumulating knowledge of the range and abundance of bacteria 
in the diverse, dynamic and spatially heterogeneous lower airway 
communities, the contribution of obligate and non-target facultative anaerobic 
bacteria (henceforth referred to collectively as “anaerobic bacteria”) to the 
pathogenesis of CF lower airway disease is currently not well understood. In 
fact, there remains much deliberation about whether anaerobic bacteria are 
pathogenic in the CF lower airways, commensals with negligible clinical 
impact or members of a “normal” airway microbiota. This review focuses on 
the most recent knowledge pertaining to the potential role of anaerobes 
detected within the polymicrobial communities of the CF lungs. 
 
Potential pathophysiological role of anaerobic bacteria in 
chronic lower airway infection 
Ecological analyses generally describe that a reduced bacterial diversity, 
including decreased richness of anaerobes, leads to dominance of a 
recognised pathogen and is associated with antibiotic use, increasing age and 
poorer lung function [19-22]. Furthermore, it has been  hypothesied that 
certain anaerobic bacteria potentially form part of a normal airway microbiota; 
the most frequently identified anaerobic genera (Prevotella, 83%; Veillonella, 
54%) in CF sputum were also commonly detected in induced sputum of 
healthy controls [23*].  
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Variation in the abundance of anaerobic bacteria: impact on clinical 
status 
It was recently shown that worse lung function (measured by lung clearance 
index) and increased inflammation (measured by blood C-Reactive Protein) 
were associated with a lower total load of anaerobic bacteria in clinically 
stable people with CF (Figure 2) [23*]. This suggests that a more diverse lung 
microbiota is potentially associated with health whilst a lower load of 
anaerobic bacteria may reflect microbiota disruption and disease progression 
(Figure 2) [23*]. However, some anaerobes in low abundance can have an 
adverse impact on disease progression, as has been demonstrated in 
periodontal disease [24]. 
Conflicting reports of variability in microbial community composition at the 
onset of an exacerbation exist with some studies reporting within-patient 
fluctuation whilst others finding little change compared with other time-points 
[9,25,26]. Recently there has been interest pertaining to microbial physiology 
within the polymicrobial community of the CF lower airways and using a novel 
microbial culture system, the physiochemical properties of the microbiota in 
sputum were investigated [27**]. Increased gas bubbles and reduced pH in 
glass capillary tubes, indicators of fermentative metabolism, at the onset of a 
pulmonary exacerbation coincided with a high abundance of fermentative 
anaerobes in a single patient with CF [27**]. Treatment with antibiotics raised 
the pH and reduced gas production and the abundance of anaerobes [27**].  
It was also proposed that fluctuations in the abundance of specific anaerobic 
bacterial genera or species within the microbial community could potentially 
be utilised as a surrogate marker to indicate clinical status [20,28,29*]. This 
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includes the obligate anaerobes, Porphyromonas and Prevotella species, 
which when present in high relative abundance were associated with better 
lung function (measured by FEV1) [28]. In contrast, an increase in the 
abundance of the facultative anaerobe, Streptococcus anginosus group, 
correlated with poorer lung function [28]. Furthermore, detection of 
Streptococcus pyogenes in high numbers was associated with acute 
pulmonary exacerbations in a small number of adults (n=15) with CF [30] 
whilst Veillonella and Prevotella species were predicted to represent potential 
surrogate markers for the onset of a pulmonary exacerbation in another 
recent study [29*].  
 
Genetic adaptation and antimicrobial resistance  
It is evident that anaerobic bacteria persist in the CF lower airway community, 
even under continuous antibiotic pressure targeting recognised pathogens 
[31]. In order to become established members of a bacterial community, 
bacteria may undergo genetic adaptation to a specific niche. For example, 
various clonal lineages of P. aeruginosa are known to accumulate mutations 
in genes that enable adaptation of the bacterium to the dynamic CF airways 
including mutations that increase resistance to antibiotics or affect virulence 
traits (described as “pathoadaptation”) [32]. Anaerobes from the CF lower 
airways are also more resistant to antibiotics when compared to similar 
anaerobic genera from the airways of healthy control subjects [33,34]. 
Therefore, this may indicate that anaerobic bacteria are established members 
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of the lower airway community and are undergoing adaptation to antibiotic 
selective pressure within the lungs.  
Some strains of P. aeruginosa are associated with worse patient outcomes 
and similar patterns have been reported for periodontal microorganisms 
where differences in pathogenicity are observed between strains of the same 
species [35,36]. Therefore, further work is warranted to investigate genetic 
adaptations and diversity of particular anaerobic species in the CF lower 
airway environment. 
 
Potential virulence mechanisms 
Anaerobic bacteria are normal commensals but are also considered 
opportunistic pathogens, often involved in polymicrobial infections. Therefore, 
it is plausible that anaerobic bacteria could constitute members of the normal 
microbiota in health but also conceivable that they could contribute to the 
pathogenesis of chronic lung disease in people with CF via direct or indirect 
mechanisms. Recent evidence from a number of studies demonstrate that 
anaerobes may cause a host inflammatory response, interact synergistically 
with recognised CF pathogens and protect recognised pathogens from 
antibiotics by enhanced antimicrobial resistance (Figure 3). 	   	  
Inflammation of the lower airways 
Anaerobic bacteria in the CF lower airways may contribute to the 
dysregulated inflammatory response and subsequent, tissue destruction 
within the lungs [37**]. Bacteria including Prevotella melaninogenica, 
Actinomyces odontolyticus, Veillonella parvula, Fusobacterium nucleatum and 
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Streptococcus sanguinis secrete various short chain fatty acids (e.g. acetic 
acid, propionic acid, butyric acid) in vitro, which were also detected in 
micromolar amounts in bronchoalveolar lavage (BAL) fluid [37**]. Notably, 
high levels of acetic acid in BAL samples correlated with elevated levels of the 
pro-inflammatory cytokine interleukin-8 (IL-8), which is an important mediator 
of neutrophil recruitment and activation [37**]. The short-chain fatty acids 
were found to contribute to the excessive release of IL-8 by CF bronchial 
epithelial cells via a specific receptor (GPR41) that was overexpressed on the 
surface of the CF cells compared to non-CF bronchial epithelial cells [37**]. 
Another study also detected short-chain fatty acids in sputum of people with 
CF, which influenced host inflammatory responses and nitric oxide production 
and when present in low concentrations, improved the growth of P. 
aeruginosa in vitro [38**].  
 
Interaction with other microorganisms in polymicrobial communities  
Anaerobic bacteria may influence the progression of CF lower airway disease 
by inter-species interactions that enhance the pathogenicity or colonisation 
ability of recognised pathogens within the lower airways. In fact, it was 
previously hypothesised that certain anaerobes might create a favourable 
microenvironment for recognised CF pathogens to colonise, cause infection 
and subsequently dominate the lower airways (Figure 2) [27**]. 
It was also reported that co-infection of P. aeruginosa with V. parvula, in an in 
vivo murine model, resulted in the recovery of a significantly higher load of P. 
aeruginosa and greater clinical deterioration compared to infection with P. 
aeruginosa alone [39*]. Conversely, pyocyanin-producing P. aeruginosa 
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isolates may increase the virulence of obligate anaerobes. A study found that 
increased mortality was observed when mice were intra-tracheally inoculated 
with Porphyromonas gingivalis and a dose of pyocyanin at a concentration 
found in the CF airways compared to the anaerobe alone [40]. 
Biofilm formation is a feature of chronic airway infection in CF and it was 
shown that P. aeruginosa grows as a mixed biofilm in vitro with various 
Streptococcus species (e.g. viridans streptococci, Streptococcus milleri group) 
[41*,42]. Virulence factor production by P. aeruginosa was increased when 
grown as a mixed biofilm compared to without Streptococcus species [41*].  
Furthermore, in patients with bronchiectasis it was reported that detection of 
non-tuberculous mycobacteria (NTM) in BAL samples was associated with a 
higher prevalence of Prevotella species compared to non-NTM infected 
patients [43]. Therefore, Prevotella species may affect colonisation of NTM in 
chronic lung infections. 
 
Enhanced antibiotic resistance 
A high proportion of CF-associated Prevotella species were previously shown 
to produce β-lactamases [33]. In polymicrobial infections, β-lactamase-
producing bacteria may protect themselves and other members of the 
community from antimicrobial agents (the concept of “passive resistance”) 
[44]. A recent study found that a β-lactamase-producing Prevotella species 
was able to shield P. aeruginosa from the activity of ceftazidime in vitro, which 
is used to target the pathogen during treatment of pulmonary exacerbations 
[45*]. Therefore, enabling P. aeruginosa to persist in the presence of 
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ceftazidime may be an indirect method by which Prevotella species contribute 
to disease pathogenesis. 	  	  
Should anaerobes be targeted by treatment? 
There is currently a lack of evidence to conclude if anaerobic bacteria should 
be targeted when treating CF lower airway infection. Targeted treatment of 
bacteria, residing within the lungs, is also challenging with the types and 
formulations of antibiotics that are currently available. Anaerobic bacteria are 
generally susceptible to some broad-spectrum antibiotics that are routinely 
used in the management of CF lower airway infection (e.g. meropenem, 
piperacillin/tazobactam) [33]; therefore, it is likely that anaerobes are non-
specifically targeted when recognised CF pathogens are treated. 
Furthermore, systemic antibiotics may adversely affect anaerobic bacteria that 
are present in high abundance in the normal microbiota of the gastrointestinal 
tract and contribute to disruption of the intestinal microbial community 
(“dysbiosis”) [46]. CF is characterised by both local and systemic inflammation 
and evidence is accumulating that indicates a relationship exists between the 
gut microbiota and the health of the airways [47-50]. For example, disruption 
of gut homeostasis may result in immunoregulatory effects outside the 
intestinal tract, which may impact respiratory diseases including chronic 
obstructive pulmonary disease [51]. Therefore, any potential antibiotic 
treatment used to target anaerobes within the CF lower airways may need to 
be tailored to minimise adverse effects on the gut microbiota. Development of 
local therapies that specifically reduce bacterial interactions, limit the host 
inflammatory response triggered by anaerobes or minimise growth of target 
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anaerobes in the lungs, e.g. hyperbaric oxygen therapy, may offer an 
alternative [27**,37**].  
Metagenomic sequencing studies generally indicate that in the absence of 
anaerobes, the health of patients is worse. Studies are required to understand 
the activities and interactions of microbes in early-stage disease and how the 
evolution of the bacterial community towards a less diverse end-stage disease 
(as found in explanted lungs) can be prevented [52]. We have also entered 
the era of CFTR modulators (e.g. correctors and potentiators), which target 
CFTR dysfunction, and how these treatments affect development of the 
airway community has been under short-term surveillance [28,53,54] but 
longer studies are required. Furthermore, the members and functional 
characteristics of the airway microbiota are individual to a person. Based on 
analysis of lung tissue samples from a symptomatic paediatric CF patient, 
who underwent a right lower lobectomy [55,56], bacterial communities are 
also known to be spatially heterogeneous in non-end stage disease. 
Therefore, virulence of anaerobic bacteria may differ both within and between 
people with CF.  
In the future it may be possible to commence a personalised treatment 
approach that will maintain a normal microbial community, limit 
pathoadaptation of bacteria residing within the lower airways, prevent 
dominance by a recognised CF pathogen and subsequent lung damage in the 
individual. In fact, the Cystic Fibrosis Microbiome-determined Antibiotic 
Therapy Trial in Exacerbations: Results Stratified (CFMATTERS) trail is the 
first randomized, controlled trial comparing the use of microbiome-directed 
antibiotic treatment with standard therapy (tobramycin and ceftazidime) for 
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people with CF experiencing respiratory infections [57**]. In this clinical trial, 
which commenced recruitment in 2014, DNA is extracted from sputum and 
sequenced. Results are reviewed by a Consensus Expert Treatment Panel, 
who agree on a 3rd antibiotic treatment to add to standard therapy targeting P. 
aeruginosa. This 3rd antibiotic is selected to target additional bacteria detected 
in the airway microbiome.  
 
Conclusion 
Anaerobic bacteria are detected in respiratory samples provided by people 
with CF of all ages and stages of disease suggesting that they are common 
and persistent members of the lower airway community. The role of anaerobic 
bacteria in the CF lower airways might be as members of a normal airway 
microbiota with disruption of this microbiota and dominance of recognised 
pathogens responsible for disease progression. However, anaerobic bacteria 
also produce virulence factors and may contribute to a dysregulated 
inflammatory response or promote recognised CF pathogens to colonise and 
infect the lower airways. Additional studies are required to understand if 
specific anaerobic genera or species are important in health or disease of the 
CF airways and if this differs between individuals. Research investigating 
ways to prevent the evolution of the bacterial community towards a less 
diverse end-stage disease without disrupting the gut microbiota is 
commended.  
 
(Word count: 2312) 
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Key points  
• Anaerobic bacteria are commonly detected in the lower airways of people 
with CF but their clinical significance is unknown. 
• The relative abundance of anaerobes in the lower airways fluctuates over 
time. 
• A lower abundance of anaerobes has been associated with worse lung 
function suggesting that anaerobes may form part of a normal airway 
community. 
• Anaerobic bacteria produce virulence factors and may enhance 
pathogenicity and colonisation by recognised CF pathogens. 
• A personalised treatment approach might be required to prevent the 
development of a microbiota that is characteristic of end-stage lung 
disease. 
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Figure titles and legends 
 
FIGURE 1. Prevalence of recognised respiratory pathogens among 
paediatrics and adults with cystic fibrosis (UK) in 2014 (n=9432) [3].  
Abbreviation: MRSA, methicillin-resistant Staphylococcus aureus.  
(Reproduced with permission from the UK Cystic Fibrosis Trust). 
 
FIGURE 2. A potenial dynamic relationship between the relative 
abundance of anaerobic bacteria, recognised pathogens, lung function 
and inflammation in the cystic fibrosis airways over time.  
(ORIGINAL) 
 
FIGURE 3. Potential pathogenic mechanisms of anaerobic bacteria 
detected in the cystic fibrosis airways. Anaerobic bacteria may [A] 
increase the pathogenicity of recognised cystic fibrosis pathogens [B] produce 
short-chain fatty acids that exaggerate the host inflammatory response [C] 
shield recognised cystic fibrosis pathogens from treatment with antibiotics.  
(ORIGINAL) 
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